STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announced a strategic collaboration ...

STORM Therapeutics has entered a new collaboration with US‑based AlidaBio to accelerate the development of cancer therapies that target RNA modifications.

Aperture Therapeutics is advancing APRTX-003, an RNA-based antisense therapy targeting MMP9, as a potential ALS treatment.

CRISPR-Cas13, a powerful RNA-targeting technology is gaining increasing attention as a next-generation gene therapy platform due to its precision and reduced side effects. Utilizing this system, ...

RNA drugs are a new type of medicine that treat disease by influencing how cells use genetic information, rather than by ...

MILFORD, Mass., Oct. 10, 2024 /PRNewswire/ -- Waters Corporation (WAT) today introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence ...

Cancer, a disease with global impact, is intricately linked to dysregulated gene expression, which is influenced by both genetic mutations and epigenetic changes, including RNA modifications. A ...

This comprehensive review by Prof. Zili Zhang, Prof. Mei Guo, and their collaborators at Nanjing University of Chinese Medicine systematically outlines the dual role of m⁶A modification in promoting ...

Researchers from the University of Eastern Finland and Aalto University have developed a computational framework called SegPore that enhances the accuracy of RNA modification detection from direct RNA ...

< Photo 1. (From left) Professor Won Do Heo and Jihwan Yu, a Ph.D. Candidate of the Department of Biological Sciences > CRISPR-Cas13, a powerful RNA-targeting technology is gaining increasing ...

University of Chicago researchers have developed a liquid biopsy test based on modification patterns in microbiome-derived cell-free RNA that predicts colorectal cancer (CRC) with greater accuracy ...